Pyxis Oncology (PYXS) Depreciation & Amortization (CF) (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $2.9 million, up 426.73% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 million (up 51.27% YoY), and the FY2025 annual result was $4.5 million, up 51.27% from the prior year.
• Depreciation & Amortization (CF) improved to $2.9 million in Q4 2025 per PYXS's latest filing, from $527000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.9 million in Q4 2025 and troughed at $113000.0 in Q1 2021.
• A 5-year average of $538800.0 and a median of $523500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 487.37% in 2024, then tumbled 50.54% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $158000.0 in 2021, then grew by 21.52% to $192000.0 in 2022, then jumped by 259.38% to $690000.0 in 2023, then decreased by 20.29% to $550000.0 in 2024, then soared by 426.73% to $2.9 million in 2025.
• Business Quant data shows PYXS's Depreciation & Amortization (CF) at $2.9 million in Q4 2025, $527000.0 in Q3 2025, and $535000.0 in Q2 2025.